Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back
Treatment
Study for relapsed platinum-sensitive ovarian cancer
Clinicaltrials.gov identifier:NCT06888921
Study Contact Information:
Contact Amanda Harp by phone at 415-373-1029 or email at [email protected]
About the Study
This study tests whether COM701 (an anti‑PVRIG ) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, , or primary peritoneal cancer are 2:1 to COM701 or . Visits include regular safety checks and scans. The trial is open at multiple centers in the U.S., France, and Israel.
This Study is Open To:
You may be eligible if you:
- Are 18 or older and female.
- Have relapsed platinum‑sensitive epithelial ovarian, , or primary peritoneal cancer.
- Completed 2 or more prior platinum‑based treatment courses.
- In your most recent platinum regimen, received 4 or more cycles and achieved a partial or complete response.
- Previously received bevacizumab or a if eligible, and are not a candidate for (or declined) these options now.
- Have recovered from prior treatment side effects to Grade ≤1 (except ; neuropathy ≤Grade 2).
This Study is NOT Open To:
You would not be eligible if you:
- Have had 4 or more total lines of cytotoxic chemotherapy.
- Received checkpoint inhibitors before (PD‑1/PD‑L1, anti‑PVRIG, TIGIT, etc.).
- Need immunosuppressive systemic steroids (or similar) within 2 weeks before first dose.
- Have liver metastases at the start or end of the current platinum line.
- Required ascites drainage during the last two cycles of your most recent chemo or after finishing it.
- Had a bowel obstruction in the past 6 weeks.
- Have active CNS metastases, active HBV/HCV/HIV, or an uncontrolled infection.
- Are pregnant/breastfeeding, or received a live vaccine within 30 days of starting.
What the Study Involves
This is a , double‑blind, placebo‑controlled, parallel‑group maintenance trial.
- Screening/qualification: Medical history review, physical exam, labs/urine, ECG, baseline CT/MRI (within ~28 days), and tumor tissue (archival preferred; fresh biopsy if needed).
- Treatment & schedule:
- COM701 (IV) or IV every 3 weeks, up to ~2 years (max 35 doses).
- Routine visit assessments: physical exam, vitals, labs (including thyroid/liver/kidney), CA‑125, periodic ECG and per schedule.
- Imaging/monitoring:
- Year 1: scans every 9 weeks;
- Year 2: every 12 weeks;
- Additional scans if clinically indicated or at the end of treatment.
- Research samples: PK and ADA blood samples (e.g., Cycle 1, 6, 12, and 30 days post‑last dose). Optional tumor biopsy around Cycle 2/3.
- Follow‑up: End‑of‑treatment visit within 7 days; safety follow‑up at Day 30 (visit) and Days 60 & 90 (calls). If stopping for reasons other than progression, scans are performed every 9 weeks up to 1 year.
- Compensation: ask your site about reimbursement for travel/parking or other costs.
- Additional time beyond standard care: Clinic infusion every 3 weeks with research blood draws and scheduled imaging as above
Study Contact Information:
Contact Amanda Harp by phone at 415-373-1029 or email at [email protected]
Treatment
Study for relapsed platinum-sensitive ovarian cancer
Clinicaltrials.gov identifier:NCT06888921
Study Contact Information:
Contact Amanda Harp by phone at 415-373-1029 or email at [email protected]